Oncogenes And Tumour Suppressors

The Second Edition of The Oncogene and Tumour Suppressor Gene FactsBook has been completely revised, updated, and expanded by 60%. The book contains more than 80 entries on oncogenes including JUN, MYC, and RAS, as well as DNA tumour viruses, tumour suppressor genes, including p53, retinoblastoma, BRCA1, BRCA2, VHL, F2FL, and essential material on angiogenesis and metastasis, apoptosis, cell cycle control, and gene therapy. Includes much new data on this fast-moving field, including newly discovered oncogenes Summarizes the clinical association and molecular properties of all known oncogenes and tumor suppression genes Contains more than 2000 terms for reference and further research Revised to included signaling pathways, apoptosis, and metastasis

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

The second edition of this authoritative text details major advances and developments in the field, such as the identification of many new tumor suppressor genes and the striking progress in understanding signal transduction pathways leading to cell proliferation. Oncogenes, Second Edition, addresses the needs of advanced undergraduates, graduate students, medical students, physicians, and scientists by examining the current state of oncogene study and where future research may lead.

Oncogenes and tumour suppressor genes have been the focus of much research because of their role not only in cancer but also in normal cell growth and differentiation. Oncogenes and Tumour Suppressors is a unique volume that brings together a team of leading researchers to present and critically assess our current knowledge. The book covers two major areas of interest: oncogenes and signal transduction, and tumour supressors and cell cycle control. Topics covered include the mechanisms of oncogene perturbation; growth factors and their receptors in cell transformation; oncogenic cytoplasmic protein tyrosine kinases; the RAS/RAP/ERK signal transduction pathway; oncogenic transcription factors; mammalian cell cycle control; the retinoblastoma gene product and its relatives; the tumour suppressor gene p53; tumour suppressors and the inheritance of cancer; the clinical relevance of oncogenes. Oncogenes and Tumour Suppressors is a major review work that provides an unparalleled summary of our current understanding of this field as viewed by some of its leading researchers. It is of interest to all those involved in research on the cell cycle, signal transduction, and cancer biology. The book is also an excellent reference source with over 1800 selected citations to the primary literature.

The first edition of Oncogenes (1989) focused on several of the better known transforming mechanisms and surveyed a spectrum of solid tumors and hematologic malignancies. Several of the nearly 50 known oncogenes most relevant to human disease were examined. In contrast, this volume presents a very different profile and balance of subject material that reflects the rapidly changing field of molecular oncology and its newly emerging concepts. Among the most important discoveries of the past 4 years are the identification of nearly a dozen different tumor suppressor genes and the finding of an entirely new class of cancer-causing gene (bcl-2) that acts by inhibiting cell death rather than stimulating cell proliferation. This edition begins by reviewing selected malignancies in which our earlier search for clinically relevant oncogenes has led to more focused studies on gain-of-function and loss-of-function genetic abnormalities, as well as autocrine and paracrine growth factor loops known to regulate tumor physiology and malignant cell behavior. Curiously, many of these genetic and functional abnormalities are shared by several different tumor types and are not uniformly present in all tumors of the same type. This observation brings up molecular questions about the tissue-specific determinants that underlie individual cancers and also gives added impetus to the suggestion that molecular abnormalities (referred to as tumor markers) be included among the histopathologic features used for clinical diagnosis and manage ment.

A tumour suppressor gene is a gene that reduces the probability that a cell in a multicellular organism will turn into a tumor cell. A mutation or deletion of such a gene will increase the probability of the formation of a tumor. Unlike oncogenes, tumor suppressor genes generally follow the 'two-hit hypothesis', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is due to the fact that if only one allele for the gene is damaged, the second can still produce the correct protein. However, there are cases where mutations in only one allele will cause an effect. A notable example is the gene that codes for p53. Tumor suppressor genes, or more precisely, the proteins for which they code, either have a dampening or repressive effect on the regulation of the cell cycle or promote apoptosis, and sometimes do both. This book presents new and important research from throughout the world.

This comprehensive encyclopedic reference provides rapid and focused information about topics of cancer research for the clinical and basic scientist, students and informed laymen. It will be readily accessible, both electronically and in print, such that it will be of value to both the scientific community and the public.

The three sections of this volume present currently available cancer gene therapy techniques. Part I describes the various aspects of gene delivery. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic. This book will prove valuable as the volume of preclinical and clinical data continues to increase.

David Fisher, MD, PhD, and an authoritative panel of academic, cutting-edge researchers review and summarize the current state of the field. Describing the broad roles of tumor suppressors from a perspective based in molecular biology and genetics, the authors detail the major suppressors and the pathways they regulate, including cell cycle progression, stress responses, apoptosis, and responses to DNA damage. Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.